摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-4-甲基苯甲醚 | 36942-56-0

中文名称
3-溴-4-甲基苯甲醚
中文别名
7-氨基-3-无-3-头孢环-4-羧酸
英文名称
3-bromo-4-methylanisole
英文别名
2-bromo-4-methoxy-1-methylbenzene;2-bromo-4-methoxytoluene
3-溴-4-甲基苯甲醚化学式
CAS
36942-56-0
化学式
C8H9BrO
mdl
——
分子量
201.063
InChiKey
MGRYVEDNIGXKQE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    144-145.5℃
  • 沸点:
    224.7±20.0℃ (760 Torr)
  • 密度:
    1.378±0.06 g/cm3 (20 ºC 760 Torr)
  • 闪点:
    101.8±7.8℃

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2909309090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    | 室温 |

SDS

SDS:33d48f991dc8fc3fb9e01186d41c5a65
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    3-溴-4-甲基苯甲醚四溴化碳氧气 作用下, 以 乙腈 为溶剂, 反应 60.0h, 以79%的产率得到2-溴-4-甲氧基苯甲酸
    参考文献:
    名称:
    光致四溴化碳引发取代甲苯有氧氧化成羧酸
    摘要:
    据报道,在 400 nm 蓝色发光二极管的照射下,使用 CBr4 作为引发剂,将取代的甲苯有氧氧化为羧酸的温和无金属程序。
    DOI:
    10.1055/s-0039-1691534
  • 作为产物:
    描述:
    2-溴-4-硝基甲苯盐酸氢氧化钾tin硫酸 、 sodium nitrite 作用下, 以 二甲基亚砜 为溶剂, 反应 7.0h, 生成 3-溴-4-甲基苯甲醚
    参考文献:
    名称:
    Electronic Effects of Ring Substituents on Triplet Benzylic Biradicals
    摘要:
    UV irradiation of alpha-(o-alkylphenyl)acetophenones with a methoxy or cyano substituent para to the o-alkyl group of the alpha-aryl ring has revealed that a methoxy group slightly increases the stereoselectivity but not the quantum yield of indanol formation, whereas a cyano group greatly lowers both diastereoselectivity and quantum efficiency, confirming the likelihood that hydrogen-bonding of the hydroxy group to the alpha-phenyl ring plays an important role in the cyclization of the photogenerated triplet 1,5-biradical intermediates.
    DOI:
    10.1021/ol0528383
点击查看最新优质反应信息

文献信息

  • Two Stereoinduction Events in One C−H Activation Step: A Route towards Terphenyl Ligands with Two Atropisomeric Axes
    作者:Quentin Dherbassy、Jean‐Pierre Djukic、Joanna Wencel‐Delord、Françoise Colobert
    DOI:10.1002/anie.201801130
    日期:2018.4.16
    scaffolds—ortho‐orientated terphenyls presenting two atropisomeric Ar–Ar axes. These unusual structures were built up by using the C−H activation approach, and remarkably, both chiral axes were controlled with excellent stereoselectivity in a single transformation. During the reaction, not only does atroposelective functionalization of a biaryl precursor occur to establish one stereogenic axis, but an
    在这里,我们公开了原始手性支架的合成-呈现两个阻转异构Ar-Ar轴的邻位三联苯。这些不寻常的结构是通过使用CH活化方法建立的,并且值得注意的是,两个手性轴在一次转化中都具有出色的立体选择性。在反应过程中,不仅会发生联芳基前体的对映选择性官能化以建立一个立体轴,而且还会发生空前的对映立体选择性CH芳基化反应,从而生成第二个立体成因元素。这些对映体纯的邻位叔苯基具有原始的三维结构,因此为建立对映体纯的双齿配体(例如新的配体S / N-Biax和二膦酸BiaxPhos)库提供了独特的基础。
  • Propionic Acid Derivatives and Methods of Use Thereof
    申请人:Biediger Ronald J.
    公开号:US20180312523A1
    公开(公告)日:2018-11-01
    Provided herein are compounds and pharmaceutical compositions of formula I where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.
    本文提供了公式I的化合物和药物组合物,其中R1、R2、R3、R4、R5和R6如本文所述。还提供了这些化合物的药用可接受盐或立体异构体。此外,还提供了用于抑制整合素结合以治疗各种病理生理条件的方法。
  • NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
    申请人:Pragma Therapeutics
    公开号:EP3459939A1
    公开(公告)日:2019-03-27
    The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 ("mGluR7"). The present invention also relates to pharmaceutical composition comprising such compound and their use for the treatment of prevention of disorders associated with glutamate dysfunction.
    本发明涉及新颖的杂环化合物。该发明还涉及调节代谢型谷氨酸受体(mGluR)的化合物,优选是代谢型谷氨酸受体亚型7("mGluR7")。本发明还涉及包含这种化合物的药物组合物及其用于治疗或预防与谷氨酸功能障碍相关的疾病的用途。
  • [EN] 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES DE 2,3,6-TRISUBSTITUE 4-PYRIMIDONE
    申请人:MITSUBISHI PHARMA CORP
    公开号:WO2004085408A1
    公开(公告)日:2004-10-07
    A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.
    一种具有tau蛋白激酶1抑制活性的嘧啶酮衍生物,其由化学式(I)或其盐、溶剂合物或水合物表示;用于预防和/或治疗神经退行性疾病(例如阿尔茨海默病);其中Q代表CH或氮原子;R代表C1-C12烷基基团;化学式(I)的环:代表哌嗪环或哌啶环;每个X独立地代表C1-C8烷基基团、可选择性部分氢化的C6-C10芳环、茚环或类似物;m代表1到3的整数;每个Y独立地代表卤素原子、羟基、氰基、C1-C6烷基基团或类似物;n代表0到8的整数;当X和Y或两个Y基团连接在同一碳原子上时,它们可以结合形成C2-C6烷基基团。
  • [EN] INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012072691A1
    公开(公告)日:2012-06-07
    The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    本发明涉及具有式(I)定义的化合物,其中变量R1、R2、R3、m和n如权利要求1中定义,具有宝贵的药理活性。特别是,这些化合物是GPR40受体的激动剂,因此适合用于治疗和预防可以通过这种受体影响的疾病,例如代谢性疾病,特别是2型糖尿病。
查看更多